SUVEN LIFE SCIENCES LIMITED The poster presentations include patient baseline characteristics and demographics from the phase-2 PoC study on Samelisant in patients with Narcolepsy with and without Cataplexy and preclinical efficacy data indicating potential utility of samelisant in treatment of excessive daytime sleepiness in Parkinson's disease.
Details of the poster presentations are as below: Samelisant (SUVN-G3031), a Histamine 3 Receptor Inverse Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Parkinson's Disease (
About samelisant Phase-2 PoC study
Samelisant phase-2 PoC clinical study is a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 mg and 4 mg samelisant compared with placebo in narcolepsy patients with and without cataplexy. Approximately 190 adult patients were randomized at a ratio of 1:1:1 to 2 mg samelisant, 4 mg samelisant, or placebo at 58 clinical trial sites across the
About Samelisant (SUVN-G3031)
Samelisant is a novel, potent, selective, brain penetrant and orally active Histamine H3 receptor inverse agonist. H3 receptor blockade elevates histamine, norepinephrine and dopamine in brain, a potential for treatment of sleep related disorders. Samelisant exhibited wake promoting activity in orexin knockout mice (an animal model of narcolepsy) and also showed similar trend in healthy human subjects (phase-1 study observations). Pre-clinical in vitro and in vivo efficacy studies, supporting neurochemical studies, pharmacokinetic studies, safety studies and phase 1 clinical studies under US IND has been successfully completed for samelisant.
About Sleep 2023 annual meeting
SLEEP 2023 is the 37th annual meeting of the Associated Professional Sleep Societies (APSS), a joint venture of the
About Narcolepsy
Narcolepsy is a chronic, debilitating neurological disorder characterized by excessive daytime sleepiness (EDS) and intermittent, uncontrollable episodes of falling asleep during the daytime. These sudden sleep attacks may occur during any type of activity at any time of the day. Narcolepsy is segmented into 2 categories: narcolepsy type 1 (with cataplexy, a sudden loss of muscle tone) and narcolepsy type 2 (without cataplexy). About one in 2,000 people have some form of narcolepsy. Symptoms present in the teens or early twenties, but occasionally occur as early as 5 years of age or after 40 years old.
About
Suven is a clinical stage biopharmaceutical company, focused on discovering and developing novel pharmaceutical products, for central nervous system ('CNS') disorders. Our focus has been on discovery and development of innovative molecules targeting diseases and areas, which has undiscovered medical treatment opportunities. Our Company singularly focuses on development of 'New Chemical Entities' ('NCEs') molecules for CNS diseases such as Alzheimer's, various forms of Dementia, Narcolepsy, Major Depressive Disorder ('MDD'), Attention Deficient Hyperactivity Disorder ('ADHD'),
Contact:
Tel: 91 40 2354 1142
Fax: 91 40 2354 1152
Email: info@suven.com
Web: www.suven.com
(C) 2023 Electronic News Publishing, source
